{"filing":{"accession_number":"0001493152-26-044451","cik":"0001582554","ticker":"MTNB","company_name":"Matinas BioPharma Holdings, Inc.","form":"8-K","filing_date":"2026-09-28","report_date":"2026-09-25","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1582554/000149315226044451/form8-k.htm"},"events":[{"id":35312,"run_id":32520,"accession_number":"0001493152-26-044451","anchor_item_number":null,"event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"The filing discloses a one-for-fifteen reverse stock split of Matinas BioPharma's common stock, effective September 28, 2026, pursuant to a Certificate of Amendment filed with Delaware and previously approved by stockholders on June 23, 2025. While a reverse stock split is a capital structure modification affecting all shareholders uniformly, it is a governance matter (amendment to articles of incorporation) rather than a specific named event type. The reverse split is material to investors as it affects share count, trading price, and the terms of all outstanding securities including options and warrants.","company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","filing_date":"2026-09-28","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":39326,"accession_number":"0001493152-26-044451","item_number":null,"item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses a one-for-fifteen reverse stock split of Matinas BioPharma's common stock, effective September 28, 2026, pursuant to a Certificate of Amendment filed with Delaware and previously approved by stockholders on June 23, 2025. While a reverse stock split is a capital structure modification affecting all shareholders uniformly, it is a governance matter (amendment to articles of incorporation) rather than a specific named event type. The reverse split is material to investors as it affects share count, trading price, and the terms of all outstanding securities including options and warrants.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T12:06:27.454025+00:00","company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","filing_date":"2026-09-28"}]}